AstraZeneca sketches plans for a $1B venture fund — and it’s going to China


Looking to the world’s second largest healthcare market, AstraZeneca is helping set up a life sciences venture fund to groom Chinese startups that could turn into potential partners.


CEO Pascal Soriot aims to raise $1B over the next four years. The short-term goal for this year is to raise $200M to $300M, and firms such as Sequoia Capital and Temasek have already expressed interest.


Read the full article at…


Leave a Reply

Your email address will not be published. Required fields are marked *

More in News & Trends
Amgen exits neuroscience R&D as pharma pulls back from field

Amgen is stopping its neuroscience research – with the exception of programs centered on neuro-inflammation – as the company concluded...